AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8971958
Drug: 1 microgram
RxNorm normalized name: Alfacalcidol 1 microgram oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 microgram of 1,25(OH)2D3 administered orally for 7 days
Trial: 8971958
Drug: 0.5 microgram
RxNorm normalized name: calcitriol 0.5 MICROGRAM In 1 CAPSULE ORAL CAPSULE, LIQUID FILLED [Rocaltrol]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 microgram of 1,25(OH)2D3 administered orally for 7 days
Trial: 1737537
Drug: Topical 0.075%
RxNorm normalized name: capsaicin topical 0.075% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.075% capsaicin cream (open-label study)
Trial: 6393805
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate (2 g intramuscular injections at 6-hr intervals)
Trial: 7723978
Drug: Placebo (normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (normal saline injections)
Trial: 31596461
Drug: Gabapentin (preoperative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin (preoperative 15 mg/kg, postoperative 7.5 mg/kg two times per day for three days)
Trial: 28212463
Drug: AZD5423 (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD5423 (inhaled selective glucocorticoid receptor modulator)
Trial: 28212463
Drug: Reference glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference glucocorticoid receptor agonist (double the approved dose)
Trial: 23972320
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (montelukast 4 mg and levocetirizine 2.5 mg/5 ml)
Trial: 23972320
Drug: Levocetirizine 2.5
RxNorm normalized name: Levocetirizine 2.5mg/5mL Oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levocetirizine 2.5 mg/5 ml
Trial: 21711959
Drug: Montelukast and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast and Levocetirizine combination
Trial: 21711959
Drug: Montelukast and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast and Antihistamine combinations
Trial: 11072942
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium butyrate (80 mmol/L, 80 mL/24 h)
Trial: 11072942
Drug: Topical sodium
RxNorm normalized name: sodium fluoride .0176 g in 1 g / HYDROFLUORIC ACID 0.010 g in 1 g DENTAL AEROSOL, FOAM [DENTI-CARE TOPICAL SODIUM FLUORIDE STRAWBERRY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical sodium butyrate (after switching from saline)
Trial: 8649634
Drug: Intramuscular vaccination
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular vaccination (40 micrograms at 0, 1, and 3 months)
Trial: 1534476
Drug: Transdermal estrogen
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal estrogen (0.1 mg of 17 beta-estradiol via dermal patches for days 1 to 21 and oral medroxyprogesterone acetate for days 11 to 21 of a 28-day cycle)
Trial: 24271137
Drug: Evacetrapib 1200
RxNorm normalized name: Evacetrapib
DrugBank: Evacetrapib (DB11655)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evacetrapib 1200 mg daily for 10 days
Trial: 24271137
Drug: Moxifloxacin 400
RxNorm normalized name: moxifloxacin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg for 1 day (positive control)
Trial: 17389552
Drug: PTC124 single-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC124 single-dose administration (3 to 200 mg/kg, specifically 50 mg/kg for pharmacokinetics)
Trial: 17389552
Drug: PTC124 multiple-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC124 multiple-dose administration (10 to 50 mg/kg/dose twice per day for up to 14 days)
Trial: 17389552
Drug: PTC124 pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTC124 pharmacokinetics
Trial: 15786487
Drug: Escitalopram (initiated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (initiated at 10 mg/day, increased to a maximum of 20 mg/day)
Trial: 11235922
Drug: Ziprasidone i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone i.m. 10 mg
Trial: 11235922
Drug: Ziprasidone i.m.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone i.m. 2 mg
Trial: 7921531
Drug: 16 alpha-gitoxin
RxNorm normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 alpha-gitoxin (2.5 to 15 mg, i.v. or oral)
Trial: 7921531
Drug: 16 alpha-gitoxin
RxNorm normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 alpha-gitoxin (5 mg i.v.)
Trial: 7921531
Drug: 16 alpha-gitoxin
RxNorm normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 alpha-gitoxin (10 mg oral)
Trial: 7921531
Drug: 16 alpha-gitoxin
RxNorm normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 alpha-gitoxin (7.5 mg)
Trial: 7921531
Drug: 16 alpha-gitoxin
RxNorm normalized name: 16-alpha-Hydroxyestradiol
DrugBank: Estriol (DB04573)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 alpha-gitoxin (various doses)
Trial: 3048090
Drug: Cefixime 400
RxNorm normalized name: cefixime 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime 400 mg once daily for 10 days
Trial: 3048090
Drug: Amoxicillin 250
RxNorm normalized name: amoxicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 250 mg three times daily for 10 days
Trial: 29193126
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg azeloprazole sodium
Trial: 29193126
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg azeloprazole sodium
Trial: 29193126
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg azeloprazole sodium
Trial: 29193126
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg rabeprazole sodium
Trial: 29193126
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg rabeprazole sodium
Trial: 29193126
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg azeloprazole sodium (before a meal)
Trial: 23160722
Drug: Yogurt drink
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yogurt drink (doogh) fortified with 500 IU vitamin D/250 mL for 12 weeks
Trial: 18308250
Drug: Rapid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid treatment (COJEC regimen: cisplatin, vincristine, carboplatin, etoposide, cyclophosphamide)
Trial: 18308250
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (OPEC and OJEC regimens: vincristine, cisplatin, etoposide, cyclophosphamide)
Trial: 16219350
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of recombinant erythropoietin (r‐EPO) and thalidomide
Trial: 10750335
Drug: H 50
RxNorm normalized name: INH 50 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H 50 mg
Trial: 10750335
Drug: H 100
RxNorm normalized name: Gentle Touch 100mm
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H 100 mg
Trial: 9421123
Drug: OME/AMO (Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OME/AMO (Omeprazole 2 x 40 mg and Amoxicillin 4 x 500 mg)
Trial: 9421123
Drug: OME/AMO/BSC (Omeprazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OME/AMO/BSC (Omeprazole 2 x 40 mg, Amoxicillin 4 x 500 mg, and Bismuth Subcitrate 4 x 120 mg)
Trial: 26312597
Drug: Teriparatide therapy
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide therapy (20 µg twice daily) for 1 week
Trial: 26312597
Drug: Teriparatide therapy
RxNorm normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Teriparatide therapy and Standard treatment (control)
Trial: 21498114
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate (NaHCO(3)) ingestion (0.3 g kg(‐1) body mass)
Trial: 19140238
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg glyceryl trinitrate
Trial: 19140238
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg vitamin C (placebo)
Trial: 17711595
Drug: Elastic compression
RxNorm normalized name: elastin
DrugBank: Elastin (human) (DB15364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elastic compression stockings (ECS) worn daily on the DVT-affected leg for 2 years
Trial: 17711595
Drug: Placebo (inactive)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (inactive) stockings worn daily on the DVT-affected leg for 2 years
Trial: 12752398
Drug: Intramuscular infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular infusion of a combination of bradykinin, serotonin, histamine, and prostaglandin E2
Trial: 9821565
Drug: 0.5 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mol/L sodium lactate
Trial: 2506844
Drug: Centrophenoxine (CPH)
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 1.11 g in 13.0 mL TOPICAL SPRAY [CPH Anti-bacterial Breath Mist]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Centrophenoxine (CPH) 2 g/day for 8 weeks
Trial: 2506844
Drug: Placebo tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets for 8 weeks
Trial: 823433
Drug: 3.5% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.5% amino acid solution
Trial: 6101516
Drug: Propranolol maintained
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol maintained until the day of surgery, half the usual dose given 2 hours prior to surgery, and intravenous propranolol administered every four hours postoperatively (group IV, n=19)
Trial: 6101516
Drug: No propranolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No propranolol therapy (group I, n=17)
Trial: 28377173
Drug: Alfacalcidol 1
RxNorm normalized name: alfacalcidol 1 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfacalcidol 1 μg daily for 4 months
Trial: 28377173
Drug: Standard asthma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard asthma treatment only
Trial: 24225560
Drug: L-arginine (ARG;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-arginine (ARG; 0.075 g·kg‐1 body mass)
Trial: 9457092
Drug: Active warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active warfarin and active aspirin (WA)
Trial: 9457092
Drug: Active warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active warfarin (W)
Trial: 9457092
Drug: Active aspirin
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active aspirin (A)
Trial: 9457092
Drug: Warfarin or
RxNorm normalized name: warfarin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin or aspirin
Trial: 7616989
Drug: Zidovudine (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zidovudine (250 mg twice daily)
Trial: 201111
Drug: D-thyroxin (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-thyroxin (4 mg/die)
Trial: 30624885
Drug: Bicyclic RGD
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicyclic RGD peptides (e.g., CT3HPQcT3RGDcT3, CT3HPQCT3RGDcT3, CT3HSQCT3RGDcT3)
Trial: 26049181
Drug: 200 mg/d
RxNorm normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg/d hydrocortisone intravenous infusion lasting for 2 hours (control group)
Trial: 26049181
Drug: 8.33 mg/h
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8.33 mg/h hydrocortisone per hour with an intravenous pump (research group)
Trial: 18586692
Drug: More positive
RxNorm normalized name: polyurethane-35 (not more than MPA.S at 40 %)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: More positive medication attitudes
Trial: 18586692
Drug: Change toward
RxNorm normalized name: monofluorophosphate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Change toward more positive medication attitudes
Trial: 15220594
Drug: Untreated silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated silicone breast implant rupture
Trial: 15220594
Drug: Intact silicone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intact silicone breast implants
Trial: 12208405
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg given as twice daily subcutaneous injections)
Trial: 2759546
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide‐5‐mononitrate (1-hour post-administration)
Trial: 2759546
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg isosorbide‐5‐mononitrate (7-day administration)
Trial: 356719
Drug: Prazosin (1-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin (1-2 mg t.i.d.)
Trial: 356719
Drug: Prazosin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin + Hydrochlorothiazide (25 mg daily for 3 weeks)
Trial: 356719
Drug: Prazosin +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prazosin + Hydrochlorothiazide + Clonidine (low doses for 6 weeks)
Trial: 27194393
Drug: Self-regulated modified
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-regulated modified constraint-induced movement therapy (SR-mCIMT)
Trial: 27194393
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy (mCIMT)
Trial: 20558084
Drug: Antibody-directed therapy
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibody-directed therapy (rituximab and intravenous immune globulin (IVIG), or IVIG alone)
Trial: 20558084
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for DSA
Trial: 10071982
Drug: Capecitabine 1250
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m2 alone (treatment A)
Trial: 10071982
Drug: Capecitabine 1250
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m2 followed immediately by Maalox (treatment B)
Trial: 10071982
Drug: Capecitabine 1250
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine 1250 mg/m2 followed 2 hours later by Maalox (treatment C)
Trial: 7551385
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen (O2) delivered via nasal cannula at 1 L/min for 4 hours
Trial: 7551385
Drug: Room air
RxNorm normalized name: air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Room air delivered via nasal cannula at 1 L/min for 4 hours
Trial: 1971651
Drug: Single pre-operative
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pre-operative dose of 1 g ceftazidime (im or iv) 1 hour before surgery
Trial: 1971651
Drug: Three peri-operative
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three peri-operative doses of 1 g ceftazidime (im or iv) 1 hour before, and 6 and 12 hours after surgery
Trial: 30395857
Drug: Heparin‐based coating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin‐based coating (Carmeda; Medtronic)
Trial: 17461296
Drug: Rimonabant 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimonabant 20 mg/day in patients with type 2 diabetes
Trial: 12064363
Drug: G‐CSF donor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF donor priming (3 to 4 micro/kg per day for 7 days prior to marrow harvest)
Trial: 12064363
Drug: G‐CSF donor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G‐CSF donor priming
Trial: 9800936
Drug: Antibodies against
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies against copper-oxidised LDL
Trial: 9800936
Drug: Antibodies against
RxNorm normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibodies against MDA-LDL
Trial: 23757474
Drug: Carbohydrate supplementation
RxNorm normalized name: pyrrolidone carboxylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbohydrate supplementation (CHO) - 800 mL the evening before and 400 mL 2 hours before surgery
Trial: 19933596
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) at a target dose of 3.0 g/day
Trial: 19933596
Drug: Intravenous cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous cyclophosphamide (IVC) at a dose of 0.5‐1.0 g/m(2)/month
Trial: 19933596
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVC)
Trial: 16367881
Drug: Glibenclamide plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glibenclamide plus metformin
Trial: 12679163
Drug: Nutritional supplement
RxNorm normalized name: Nutritional supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplement (400 kcal, 15 g protein, 50% of vitamin DRVs) and resistance exercise training
Trial: 11147228
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment protocols for remission induction and postremission treatment in ALL
Trial: 9377606
Drug: Losartan (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (10 to 150 mg once daily, most commonly 50 to 100 mg per day)
Trial: 20118146
Drug: Intranasal application
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal application of xenon at a rate of 1.0 litre h(‐1) for 30 min
Trial: 15911152
Drug: Flexible-dose pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Flexible-dose pregabalin (150, 300, 450, and 600 mg/day with weekly dose escalation)
Trial: 15911152
Drug: Fixed-dose pregabalin
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fixed-dose pregabalin (300 mg/day for 1 week followed by 600 mg/day for 11 weeks)
Trial: 8143220
Drug: Sotalol (173.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotalol (173.3 +/- 59.8 mg/day)
Trial: 8143220
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (13 on amiodarone and 3 on beta-blockers)
Trial: 27862905
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (INF) 2 μg/kg, maximum 100 μg
Trial: 27862905
Drug: Placebo (intranasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (intranasal saline)
Trial: 23082885
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no ASA therapy)
Trial: 16722388
Drug: Yanshu injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yanshu injection combining with chemotherapy
Trial: 14742225
Drug: Sulfadiazine 2,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadiazine 2,000 mg administered twice daily (BID)
Trial: 14742225
Drug: Sulfadiazine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfadiazine 1,000 mg administered four times a day (QID)
Trial: 31104505
Drug: Sumatriptan (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (6 mg s.c.)
Trial: 28481338
Drug: Glutinous brown
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutinous brown rice (GBR) twice a day for 8 weeks
Trial: 21887811
Drug: Internet intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Internet intervention (unguided self-help intervention with a depression information website and automated cognitive behavioural therapy)
Trial: 19447767
Drug: Glucocorticoid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucocorticoid therapy (prednisolone or equivalent)
Trial: 15384026
Drug: Candesartan 8
RxNorm normalized name: candesartan 8 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 8 mg daily for 4 weeks
Trial: 15384026
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg daily for 4 weeks
Trial: 15384026
Drug: Both drugs
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both drugs (Candesartan and Enalapril)